World’s First Human Implant of a 3D-Printed Cornea Restores Sight
December 15, 2025
Brand Name :
Prevnar 20
Synonyms :
pneumococcal vaccine 20-valent
Class :
Vaccines, Inactivated, Bacterial
Dosage Forms & StrengthsÂ
SuspensionÂ
0.5 ml single-dose prefilled syringeÂ
Group B Streptococcus (GBS) InfectionsÂ
Administer dose of 0.5 ml intramuscularly for one time a day
Dosage Forms & StrengthsÂ
SuspensionÂ
0.5ml single-dose prefilled syringeÂ
Group B Streptococcus (GBS) InfectionsÂ
Aged 6 weeks through 15 months
4-dose series:
Administer dose of 0.5 ml intramuscularly at 2 months, 4 months, 6 months and then for 12 to 15 months
First dose may be given as early as possible at time of 6 weeks of age
Individuals starting vaccination at aged 7 months through 17 years old
7 to 11 months: as 3 dose series
Administer first 2 doses minimum four weeks apart and then third dose after 1 year, apart from the second dose by at least 2 months
12 to 23 months: as 2 doses series
Administer minimum 2 months apart
>24 months: Administer 1 dose
Refer to adult dosingÂ
Actions and SpectrumÂ
Pneumococcal vaccine 20-valent is to stimulate the immune system to produce an immune response against the targeted pneumococcal serotypes. The vaccine contains polysaccharides from the outer coating of the bacteria, which are conjugated to a carrier protein.
Frequency defined Â
>10%Â
Muscle pain Â
Fatigue Â
Headache Â
ArthralgiaÂ
Fatigue Â
Headache Â
Pain at injection site Â
Arthralgia Â
Pain at injection site Â
Muscle pain Â
Post marketing ReportsÂ
AnaphylacticÂ
Angioneurotic edemaÂ
Lymphadenopathy localized to injection site regionÂ
Black Box WarningÂ
NoneÂ
Contraindication/Caution:Â
Contraindication:Â
Caution:Â
Pregnancy consideration:Â
Pregnancy category: N/AÂ
Lactation: Excretion into human milk is unknown Â
Pregnancy Categories:        Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women. Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.Â
Category N: There is no data available for the drug under this category.Â
Pharmacology Â
Pneumococcal vaccine 20-valent is a conjugate vaccine that contains polysaccharides from the outer coating of 20 different serotypes of Streptococcus pneumoniae bacteria. Â
These polysaccharides are chemically linked to a carrier protein.Â
PharmacodynamicsÂ
The vaccine maintains elevated antibody levels over an extended period, providing long-term protection against the targeted pneumococcal serotypes.Â
PharmacokineticsÂ
Limited information available on ADME.Â
Administration Â
Pneumococcal vaccine 20-valent is administered via intramuscular injection.Â
Patient information leafletÂ
Generic Name: pneumococcal vaccine 20-valentÂ
Why do we use pneumococcal vaccine 20-valent?Â
Pneumococcal vaccine 20-valent is indicated to protect against invasive pneumococcal disease.  Â
Pneumococcal vaccine 20-valent is help in the reduction of risk of pneumonia caused by the targeted pneumococcal serotypes.Â